CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Atreca Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Atreca Inc
835 Industrial Road
, 75 SHOREWAY ROAD, SUITE C
Phone: (650) 595-2595p:650 595-2595 SAN CARLOS, CA  94070  United States Fax: (650) 453-2410f:650 453-2410
This company ceased filing statements with the SEC on 4/1/2024.
Atreca Inc. ceased operations in 2024.
This company is no longer actively traded on any major stock exchange.
Business Summary
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Brian G.Atwood 70 12/1/2013 12/1/2013
President, Chief Executive Officer, Principal Financial Officer, Director John A.Orwin 59 9/22/2023 4/1/2018
Co-Founder, Director Tito A.Serafini 59 1/31/2024
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 90 (As of 12/31/2022)
Outstanding Shares: 45,153,725 (As of 4/16/2024)
Shareholders: 50
Stock Exchange: OTC
Federal Tax Id: 273723255
Fax Number: (650) 453-2410
Email Address: info@atreca.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024